NASDAQ Archives

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Group2024-10-29T13:56:49+02:00October 25, 2024|Press Releases, Investor Information, Psychedelic News|

Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions. Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Psyence Group2024-10-29T13:46:46+02:00October 14, 2024|Psychedelic News, Press Releases, Investor Information|

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Group Provides Corporate Update Following Succesful SPAC Spin Out Of Therapeutic Division

Psyence Group2024-03-11T14:36:36+02:00March 11, 2024|Press Releases, Investor Information, Psychedelic News|

Psyence Biomed II Corp. ("Psyence Biomed"), the therapeutics division of Psyence Group and target business of the Business Combination, is now a wholly-owned subsidiary of NASDAQ traded PBM.